Ameren Corporation filed a Form 8-K with the SEC on September 18, 2026, reporting the sale of $900 million principal amount of Junior Subordinated Notes due 2057 and attaching related transaction documents as exhibits.
Nanobiotix (NASDAQ:NBTX) shares pulled back sharply in Friday's session as investors booked profits and digested mixed new clinical data, following a rally that had taken shares up roughly 283% over the past year. Nanobiotix is a Paris-based, late clinical-stage biotechnology company pioneering physics-based nanotherapeutics, …
Xenon Pharmaceuticals (NASDAQ:XENE) shares extended their decline through Friday's session, falling as much as 30.39% by the afternoon after opening the day down roughly 24% following the company's disclosure of a voluntary pause in new patient enrollment for its azetukalner studies in major depressive …
XORTX Therapeutics (NASDAQ:XRTX) shares jumped in Friday's session after the company outlined its anticipated Investigational New Drug application submission to the FDA for its XRx-026 gout program, planned for the fourth quarter of 2026. XORTX is a late-stage clinical pharmaceutical company headquartered in Calgary, …
Alaunos Therapeutics, Inc. (Nasdaq:TCRT) has priced a registered direct offering, agreeing to sell 380,469 shares of common stock alongside pre-funded warrants covering up to an additional 386,654 shares. The offering price of $1.46 per share was set at-the-market underNasdaqrules, and the transaction is expected …
Halozyme Therapeutics, Inc. (Nasdaq:HALO) has priced 1.3 billion dollars in aggregate principal amount of convertible senior notes due 2033, carrying a 1.50% annual interest rate. The offering size was increased from an originally announced 1.05 billion dollars, with initial purchasers also granted an option …
BlossomHill Therapeutics, Inc. (Nasdaq:BLSM), a clinical-stage oncology company, has reported financial results for the second quarter of 2026, its first as a publicly traded company following an initial public offering completed in August. The IPO generated approximately 168.3 million dollars in gross proceeds through …
XORTX Therapeutics Inc. (NASDAQ:XRTX), a late-stage clinical pharmaceutical company, has outlined plans to submit an Investigational New Drug application to the FDA in the fourth quarter of 2026 for its XRx-026 gout program. The filing represents a defined step in the company's broader strategy …
Corcept Therapeutics Incorporated (NASDAQ:CORT) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending that the European Commission approve relacorilant, marketed as Lifyorli, in combination with nab-paclitaxel chemotherapy for platinum-resistant ovarian cancer. The recommendation moves the …
Alkermes (NASDAQ:ALKS) shares fell sharply in Friday's session, sharply underperforming the broader healthcare sector, which has been relatively firm amid a market rebound following the Federal Reserve's rate decision. Alkermes is a fully integrated, Dublin, Ireland-headquartered biopharmaceutical company that develops, manufactures, and commercializes medicines …